Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17229641 | 1.00 | RBP4 (1.00) | RBP4 | |
| SCHEMBL17222920 | 0.93 | RBP4 (0.88) | RBP4 | |
| SCHEMBL29813075 | 0.93 | RBP4 (0.88) | RBP4 | |
| SCHEMBL17229901 | 0.91 | RBP4 (1.00) | RBP4 | |
| SCHEMBL17229642 | 0.91 | RBP4 (0.84) | RBP4 | |
| SCHEMBL17222973 | 0.88 | RBP4 (1.00) | RBP4 | |
| SCHEMBL29813277 | 0.88 | RBP4 (1.00) | RBP4 | |
| SCHEMBL25438914 | 0.88 | RBP4 (0.77) | RBP4 | |
| SCHEMBL24727633 | 0.87 | RBP4 (0.78) | RBP4 | |
| SCHEMBL29798772 | 0.87 | RBP4 (1.00) | RBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12364693-B2 | Methods of treating metabolic diseases with fused bicyclic pyrazoles | BELITE BIO, INC (US) | 2025-07-22 | — | — | US | disclosed |
| EP-4507566-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | Belite Bio, Inc (US) | 2025-02-19 | — | — | EP | disclosed |
| EP-4436577-A1 | TABLET FORMULATIONS OF RBP4 INHIBITORS AND METHODS OF USE | Belite Bio, Inc (US) | 2024-10-02 | — | — | EP | disclosed |
| EP-4340701-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | Belite Bio, LLC (US) | 2024-03-27 | — | — | EP | disclosed |
| WO-2023200766-A1 | METHODS, COMPOSITIONS AND SYSTEMS FOR EVALUATION OF VISUAL FUNCTION | BELITE BIO, INC (US) | 2023-10-19 | — | — | WO | disclosed |
| WO-2023097221-A1 | TABLET FORMULATIONS OF RBP4 INHIBITORS AND METHODS OF USE | BELITE BIO, INC (US) | 2023-06-01 | — | — | WO | disclosed |
| WO-2022246238-A1 | BIOMARKERS FOR AGE-RELATED MACULAR DEGENERATION | BELITE BIO, LLC (US) | 2022-11-24 | — | — | WO | disclosed |
| US-20220354844-A1 | METHODS OF TREATING METABOLIC DISEASES WITH FUSED BICYCLIC PYRAZOLES | BELITE BIO, INC. (KY) | 2022-11-10 | — | — | US | disclosed |
| US-11389444-B2 | Methods of treating metabolic diseases with fused bicyclic pyrazoles | BELITE BIO, INC (KY) | 2022-07-19 | — | — | US | disclosed |
| EP-3996714-A1 | FORMULATIONS OF RBP4 INHIBITORS AND METHODS OF USE | Belite Bio, LLC (US) | 2022-05-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220354844-A1 | METHODS OF TREATING METABOLIC DISEASES WITH FUSED BICYCLIC PYRAZOLES | RBP4, RBP1, FABP4 | RBP4 1/4885 |
| US-12364693-B2 | Methods of treating metabolic diseases with fused bicyclic pyrazoles | RBP4, RBP1, FABP4 | RBP4 1/4885 |
| US-11389444-B2 | Methods of treating metabolic diseases with fused bicyclic pyrazoles | RBP4, RBP1, FABP4 | RBP4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.